Hospital
Tmc/Higgins General Hospital
Tmc/Higgins General Hospital was paid $12.23M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoTMC/HIGGINS GENERAL HOSPITAL
BREMEN, GA 30110
BREMEN, GA 30110
33aNPI1194712083assigned 10/05/2005
33bProvider typeCritical Access Hospital
28Total paid$12.23M
24GClaims236,452
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,515 | $1.69M | |
| 2019 | 32,977 | $1.63M | |
| 2020 | 27,352 | $1.02M | |
| 2021 | 35,288 | $1.63M | |
| 2022 | 39,172 | $2.24M | |
| 2023 | 40,039 | $2.26M | |
| 2024incomplete | 28,109 | $1.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 19,876 | 18,688 | $2.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 10,859 | 10,184 | $2.37M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 11% | 2,119 | 2,039 | $1.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 2,669 | 2,496 | $635K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 2,140 | 2,038 | $496K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.0% | 12,851 | 3,605 | $492K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 4,960 | 4,789 | $414K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.0% | 689 | 661 | $369K |
| 87428 | 2.4% | 6,461 | 6,246 | $293K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 4,950 | 4,421 | $233K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.8% | 3,822 | 3,662 | $224K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 3,453 | 2,454 | $211K |
111 more codes
| 71045 | Radiologic examination, chest; single view | 1.7% | 5,182 | $203K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 4,129 | $192K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 5,356 | $189K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 6,174 | $154K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 3,127 | $150K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.1% | 2,113 | $139K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 4,361 | $129K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,742 | $103K |
| 80053 | Comprehensive metabolic panel | <1% | 11,468 | $82K |
| 97014 | <1% | 3,101 | $78K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,904 | $71K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,860 | $55K |
| 97161 | <1% | 1,508 | $52K | |
| 74018 | <1% | 652 | $41K | |
| 72100 | <1% | 779 | $41K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,557 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 654 | $37K |
| 73630 | <1% | 698 | $35K | |
| 96376 | <1% | 1,033 | $32K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,097 | $31K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 100 | $31K |
| 84484 | <1% | 3,204 | $30K | |
| 73610 | <1% | 478 | $24K | |
| 81025 | <1% | 4,062 | $20K | |
| 73130 | <1% | 381 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 101 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,366 | $17K |
| 83880 | <1% | 611 | $14K | |
| 71250 | <1% | 51 | $13K | |
| 81001 | <1% | 6,850 | $13K | |
| 83690 | <1% | 2,737 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,358 | $12K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 27 | $12K |
| 87807 | <1% | 1,580 | $12K | |
| 73560 | <1% | 303 | $11K | |
| 87088 | <1% | 2,302 | $11K | |
| 87430 | <1% | 1,409 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 28 | $10K |
| 73030 | <1% | 183 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 13,183 | $9K |
| 97164 | <1% | 774 | $8K | |
| 76000 | <1% | 107 | $8K | |
| 97162 | <1% | 252 | $8K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 107 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 30 | $8K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 14 | $7K |
| 87070 | <1% | 1,212 | $7K | |
| 87040 | <1% | 578 | $6K | |
| 73110 | <1% | 164 | $6K | |
| 85379 | <1% | 758 | $6K | |
| 87186 | <1% | 1,004 | $6K | |
| 82962 | <1% | 2,591 | $5K | |
| 87077 | <1% | 1,106 | $5K | |
| 83605 | <1% | 631 | $5K | |
| 81003 | <1% | 3,339 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,504 | $5K |
| 83735 | <1% | 1,358 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 295 | $4K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 134 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 166 | $4K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 196 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,033 | $3K |
| 76536 | <1% | 14 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 664 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,319 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 134 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 360 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,166 | $2K |
| 76775 | <1% | 12 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 90 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,148 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,421 | $1K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 549 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 90 | $1K |
| 86140 | <1% | 331 | $1K | |
| 85610 | <1% | 411 | $1K | |
| 85027 | <1% | 301 | $950.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,739 | $929.05 |
| 73502 | <1% | 19 | $609.15 | |
| 73080 | <1% | 15 | $603.42 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 935 | $389.67 |
| 82550 | <1% | 161 | $387.23 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 344 | $363.47 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 20 | $359.58 |
| 80061 | Lipid panel | <1% | 45 | $325.51 |
| J2704 | Injection, propofol, 10 mg | <1% | 218 | $301.46 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 71 | $281.44 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,915 | $280.41 |
| 84703 | <1% | 44 | $262.18 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 324 | $253.12 |
| 87210 | <1% | 41 | $191.13 | |
| 85730 | <1% | 43 | $154.40 | |
| 84702 | <1% | 29 | $153.17 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 42 | $131.73 |
| 73090 | <1% | 13 | $127.54 | |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 205 | $117.42 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 85 | $103.36 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,089 | $91.80 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 26 | $67.82 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 26 | $65.08 |
| 82565 | <1% | 12 | $47.31 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 33 | $40.60 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 57 | $35.95 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 87 | $32.25 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 13 | $29.66 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 21 | $26.08 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,702 | $0.10 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 14 | $0.00 |
| C1780 | Lens, intraocular (new technology) | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHERSETH, LEE (CFO)